<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Lilly Suspends Two Studies Of Key New Drug</title>
	<atom:link href="http://www.pharmalot.com/2007/10/lilly-suspends-two-prasugrel-studies/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2007/10/lilly-suspends-two-prasugrel-studies/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 19:26:11 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: www.topcholesteroladvice.info &#187; Lilly Suspends Two Prasugrel Studies</title>
		<link>http://www.pharmalot.com/2007/10/lilly-suspends-two-prasugrel-studies/#comment-23208</link>
		<dc:creator>www.topcholesteroladvice.info &#187; Lilly Suspends Two Prasugrel Studies</dc:creator>
		<pubDate>Thu, 25 Oct 2007 12:14:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2007/10/lilly-suspends-two-prasugrel-studies/#comment-23208</guid>
		<description>[...] Ed Silverman placed an interesting blog post on Lilly Suspends Two Prasugrel Studies.Here&#8217;s a brief overview:4 at the American Heart Association meeting, Lilly has been hoping prasugrel will generate at least $1 billion annually and compete with Plavix, which is marketed by Bristol-Myers Squibb and Sanofi-Aventis. &#8230; [...]</description>
		<content:encoded><![CDATA[<p>[...] Ed Silverman placed an interesting blog post on Lilly Suspends Two Prasugrel Studies.Here&#8217;s a brief overview:4 at the American Heart Association meeting, Lilly has been hoping prasugrel will generate at least $1 billion annually and compete with Plavix, which is marketed by Bristol-Myers Squibb and Sanofi-Aventis. &#8230; [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.153 seconds -->

